1. Pink Sheet

Companies Planning UK Investment Cuts Over Repayments Predicted for 2023

 
• By Leela Barham

Many pharma firms are considering cutting their investment in clinical trials or reducing their supply to the UK market next year, a survey by industry group EMIG found.

Concept of business growth in finance. businessperson calculate income and profit on investments and an increase in the indicators of positive growth
UK industry repayments are on the rise • Source: Shutterstock

Companies are planning to cut their investment in UK clinical research and reduce their supply of medicines to the country because they are facing payments of more than a third of their sales in 2023 under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), according to a recent industry survey.

More than three quarters of 51 pharmaceutical company members of the Ethical Medicines Industry Group (EMIG) said that their business investment in UK clinical research would fall in the future

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter

Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.